Key result
Lower serum 130-kDa soluble T-cadherin levels are linked to a higher burden of metabolic risk factors.
Why the study?
Are circulating soluble T-cadherin levels associated with metabolic syndrome in a general population undergoing health checkups?
Cross-Sectional (n=1,321)
Are circulating soluble T-cadherin levels associated with metabolic syndrome in a general population undergoing health checkups?
Answers are grounded in this paper and cite their sources.
Low serum 130-kDa sT-cad levels are associated with the presence and accumulation of metabolic syndrome-related abnormalities.
AIMS: Visceral fat accumulation is the central feature of metabolic syndrome and subsequent atherosclerotic cardiovascular disease. Soluble T-cadherin (sT-cad) has been identified in circulation, but its clinical significance in the general population remains unclear. We investigated the associations of circulating sT-cad levels with metabolic syndrome and its components in a population undergoing health checkups. METHODS: A total of 1321 Japanese participants (825 males and 496 females) undergoing health checkups were enrolled. Serum levels of sT-cad (130-kDa, 100-kDa, and 30-kDa), adiponectin (APN), and other clinical parameters were measured. Associations between sT-cad and metabolic risk factors were analyzed. RESULTS: Among the three sT-cad isoforms, serum 130-kDa sT-cad levels were significantly negatively correlated with waist circumference, blood pressure, Homeostatic Model Assessment for Insulin Resistance (HOMA-R), triglycerides, Alanine aminotransferase (ALT), uric acid, and high-sensitivity C-reactive protein (hsCRP), and positively correlated with high-density lipoprotein (HDL) cholesterol and APN. In multivariate analysis, high TG levels and/or HDL-C levels and hsCRP were independent negative determinants of 130-kDa sT-cad levels in both sexes. Furthermore, 130-kDa sT-cad levels decreased progressively with an increasing number of metabolic risk factors (P for trend <0.001). CONCLUSION: Low serum 130-kDa sT-cad levels are associated with the presence and accumulation of metabolic syndrome-related abnormalities in a Japanese population undergoing health checkups. Inflammation and lipid abnormalities of metabolic syndrome (high TG and/or low HDL-C) may influence the serum 130-kDa sT-cad levels.
No takes yet. Share an insight, caveat, or question.
Mineo et al. (2025) conducted a cross-sectional in Metabolic Syndrome (n=1,321). Serum soluble T-cadherin (sT-cad) levels was evaluated on Metabolic syndrome and its components (p=<0.001). Serum 130-kDa soluble T-cadherin levels decreased progressively with an increasing number of metabolic risk factors.
Synapse has enriched 10 related papers. Consider them for comparative context: